Home » Authors » Brady Huggett

Articles by Brady Huggett

Avant Dropping TP10 Following Phase II Failure; Stock Tumbles

Feb. 21, 2002

By Brady Huggett

Vela Raises $25M In Series D To Fund Trials, Add Employees

Feb. 20, 2002

By Brady Huggett

Vela Raises $25M In Series D To Fund Trials, Add Employees

Feb. 20, 2002

By Brady Huggett

Amylin Raises $84M Publicly To Fund AC2993 Phase III Trials

Feb. 13, 2002

By Brady Huggett

Amylin Raises $84M Publicly To Fund AC2993 Phase III Trials

Feb. 13, 2002

By Brady Huggett

Deltagen Paying $23.5M For BMS Unit, Adding Discovery Capability

Feb. 12, 2002

By Brady Huggett

Deltagen Paying $23.5M For BMS Unit, Adding Discovery Capability

Feb. 12, 2002

By Brady Huggett

Immunex, Genesis Form Pact To Research, Develop Molecules

Feb. 8, 2002

By Brady Huggett

Immunex, Genesis Form Pact To Research, Develop Molecules

Feb. 8, 2002

By Brady Huggett

ZymoGenetics Raises $120M In Year’s First Biotech IPO

Feb. 4, 2002

By Brady Huggett

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 12, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
LINC01116 has prognostic value in lung cancer, study shows
BioWorld MedTech
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...